Emerging Biopharma

Sketch of lungs
Biotech

With $30M, Oorja Bio breathes new life into fibrosis candidate

The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining lung structure and stability.
Darren Incorvaia May 20, 2026 10:31am
Fierce 15 Hero

Nominations now open for Fierce Biotech's 2026 Fierce 15

May 18, 2026 9:44am
Constellation Orion

Oryon shines out of stealth with $21M to fight Parkinson's

Mar 23, 2026 5:00am
F1 Racetrack

R1 debuts with $77.5M to advance kidney disease treatment

Mar 17, 2026 7:00am
One extinguished candle on dark background

Biotech unit Pfizer Ignite flames out

Mar 12, 2026 3:58pm
Deal

French biotech pens $128M deal for Kezar protein degrader work

Mar 12, 2026 9:00am
More News

Atrium arises from Avidity buyout with $270M, preclinical assets

Feb 27, 2026 11:05am

Harbour sails with Solstice in $1.1B biobucks deal

Feb 24, 2026 2:38pm

New biotech Slate aims to solve migraine injection equation

Feb 24, 2026 7:30am

Korsana crosses into crowded Alzheimer's field with $175M

Feb 18, 2026 6:00am